The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Preliminary results with 7 versus 14-day emavusertib plus aza-ven in AML
Cristina Papayannidis, MD, PhD, University of Bologna, Bologna, Italy, discusses the preliminary results of a Phase I study (EUCT no. 2023-505828-58) in which patients with acute myeloid leukemia (AML) are treated with a 7- or 14-day dosing schedule of emavusertib added to combination therapy with azacitidine (aza) and venetoclax (ven). Dr Papayannidis highlights a promising measurable residual disease (MRD) conversion rate thus far, and notes that this combination regimen is well tolerated. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
